Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

Showing 1-10 of 627

13 Sep 2021  |  North America

Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities

Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of ph...

USD 4,950.00
27 Aug 2021  |  North America

US and EU Upstream Bioprocessing Growth Opportunities

Increasing Demand for Consumables and Single-use Technologies to Drive Growth in Upstream Bioprocessing

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

USD 4,950.00
24 Aug 2021  |  North America

US and EU Biotech Industry VC Investment Growth Opportunities

Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI

With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...

USD 2,450.00
16 Aug 2021  |  North America

Global Drug Discovery and Early Development Outsourcing Growth Opportunities

Growing Research and Development Pipelines of Emerging Biopharmaceutical and Niche Technology Providers Drive Competitive Intensity

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report ...

USD 4,950.00
12 Aug 2021  |  North America

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

USD 4,950.00
30 Jun 2021  |  North America

US & EU Direct-to-consumer Genetic Testing Market, Key Trends & Growth Opportunities

Telegenetic Counseling to Revolutionize Access to Patient Care

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

USD 2,450.00
23 Jun 2021  |  Global

Frost Radar™: Artificial Intelligence-enabled Drug Discovery in the Global Pharmaceutical Industry, 2021

A Benchmarking System to Spark Companies to Action—Innovation that Fuels New Deal Flow and Growth Pipelines

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

USD 4,950.00
23 Jun 2021  |  Global

Global RNA Therapeutics:Technology Growth Opportunities

Advances in RNA Modifications, Formulation, and Stabilization to Drive Growth of RNA Therapeutics

RNA therapeutics is a rapidly expanding area of next-generation biological drugs. RNA is a versatile molecule and naturally regulates gene expression, either by upregulation or downregulation. This function is employed to design novel RNA therapeutics. The fundamentals of RNA therapeutics consists of delivering functional RNA at a target; however, ...

USD 4,950.00
17 Jun 2021  |  North America

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

USD 4,950.00
13 May 2021  |  Global

Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market

Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the markets maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, a...

USD 4,950.00

Showing 1-10 of 627